Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT1 | Q03111 | 17/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | MLLT3 | P42568 | 4/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | YEATS2 | Q9ULM3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL215564 | 0.84 | MLLT1 (0.56) | MLLT1MAOBMLLT3NAMPTYEATS2 | |
| SCHEMBL26403781 | 0.80 | MLLT1 (0.63) | MLLT1MAOBMLLT3NAMPTYEATS2 | |
| SCHEMBL25523619 | 0.76 | MLLT1 (0.59) | MLLT1MAOBMLLT3NAMPTYEATS2 | |
| SCHEMBL15789354 | 0.73 | CYP2C9 (0.43) | MLLT1MAOB | |
| Hydrochloric Acid SCHEMBL15380752 | 0.73 | MLLT1 (0.49) | MLLT1MLLT3NAMPTYEATS2 | |
| SCHEMBL24816112 | 0.72 | DNMT1 (0.46) | MLLT1MAOBMLLT3NAMPTYEATS2 | |
| SCHEMBL173528 | 0.70 | MAOB (0.52) | MAOBNAMPT | |
| SCHEMBL9753842 | 0.70 | PTGS1 (0.59) | — | |
| SCHEMBL25332612 | 0.69 | MLLT1 (0.54) | MLLT1MLLT3NAMPTYEATS2 | |
| Hydrochloric Acid SCHEMBL15232009 | 0.69 | MAOB (0.51) | MAOBNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | disclosed |
| WO-2025122558-A1 | PYRAZINAMIDE-MIMICKING SMALL MOLECULES AS TREATMENT FOR TUBERCULOSIS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | disclosed |
| US-12180221-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-31 | — | — | US | disclosed |
| WO-2024226914-A2 | MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF | SEPTERNA, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| WO-2021229302-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-11-18 | — | — | WO | disclosed |
| EP-3768269-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2020198026-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020198026-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20200102303-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| WO-2019183587-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019183587-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-8088792-B2 | Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-10-08 | — | — | US | disclosed |
| US-5821241-A | INHIBIT BINDING OF FIBRINOGEN TO BLOOD PLATELETS, INHIBIT AGGREGATION OF BLOOD PLATELETS, PREVENT OR TREAT THROMBUS OR EMBOLUS FORMATION | MERCK & CO., INC. (US) | 1998-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | MLLT1 4718/4885MAOB 165/4885MLLT3 3877/4885 |
| US-20200102303-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MLLT1 2636/4885MAOB 225/4885MLLT3 3331/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | MLLT1 1382/4885MAOB 1186/4885MLLT3 1080/4885 |
| US-12180221-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | MLLT1 1333/4885MAOB 64/4885MLLT3 2952/4885 |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, FASN | MLLT1 1606/4885MAOB 2706/4885MLLT3 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.